Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 5,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 5,000 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the director directly owned 8,388 shares in the company, valued at approximately $167,760. The trade was a 37.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

CeriBell Stock Down 5.0%

Shares of CBLL traded down $1.07 during mid-day trading on Wednesday, hitting $20.16. 296,334 shares of the company’s stock were exchanged, compared to its average volume of 312,535. The stock’s 50-day moving average is $13.81 and its 200-day moving average is $14.42. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The company has a market cap of $747.75 million, a price-to-earnings ratio of -13.37 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. On average, sell-side analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on CBLL. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday. Raymond James Financial assumed coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, TD Cowen dropped their target price on CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.17.

Institutional Trading of CeriBell

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares during the period. Yu Fan grew its position in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after acquiring an additional 130,964 shares during the last quarter. Novo Holdings A S increased its holdings in shares of CeriBell by 2.3% in the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after acquiring an additional 20,000 shares during the period. TimesSquare Capital Management LLC increased its holdings in shares of CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after acquiring an additional 20,700 shares during the period. Finally, Millennium Management LLC raised its position in CeriBell by 41.8% in the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after purchasing an additional 196,299 shares during the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.